Key Stats for Elevance Health Stock
- Price change for Elevance Health stock: -7%
- $ELV Stock Price as of Jul. 15: $390
- 52-Week High: $436
- $ELV Stock Price Target: $441
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Elevance Health (ELV) stock dropped sharply on Wednesday even though the health insurer beat expectations on nearly every headline number.
Adjusted earnings came in at $7.45 per share, well above the $6.21 analysts expected. Revenue stood at $49.8 billion, also topping estimates of $48.6 billion. The company even raised its full-year guidance, now expecting adjusted EPS of at least $27.00.
So why did Elevance Health stock fall so much? The answer is margins.
- Operating margin slipped to 3.5%, down from 4.9% a year ago.
- Adjusted operating margin fell to 3.6% from 5.0%.
- In the company’s core Health Benefits segment, margin dropped even further, down to 2.1% from 3.8% last year.
- Investors clearly weighed those declining margins more heavily than the earnings beat itself.
- Part of the pressure came from the benefit expense ratio, which climbed 80 basis points year over year to 89.7%.
- That increase was driven by higher medical costs in the company’s government businesses, though improved performance in Individual ACA helped offset some of that pressure.
On the earnings call, CEO Gail Boudreaux said results were supported by disciplined execution and improved performance across the company’s different business lines.
She pointed to Medicare Advantage as a bright spot, with the company on track for at least a 2% operating margin there this year, thanks to deliberate portfolio changes made for 2026.
Individual ACA also performed largely as expected, with retention running ahead of plan.
Medicaid remains the trickier piece of the story.
- Elevance says 2026 is the trough year for Medicaid margins, with the segment’s full-year operating margin outlook holding at approximately negative 1.75%.
- The company recently agreed to exit the D.C. Medicaid market and plans to exit more markets over the next 12 to 18 months where it doesn’t see a path to sustainable performance.
Medical membership came in around 44.9 million, down about 469,000 from the prior quarter. That decline was tied to a known commercial fee-based customer transition, as well as expected attrition in Individual ACA and Medicaid.
The Health Benefits segment brought in $42.7 billion in revenue, up 3% year-over-year, while Carelon revenue grew 6% to $19.2 billion.
See analysts’ growth forecasts and price targets for Elevance Health stock (It’s free) >>>
What the Market Is Telling Us About Elevance Health Stock
The selloff in Elevance Health stock shows investors are looking past the earnings beat and focusing on the underlying trend in profitability.
A shrinking margin, especially in the core Health Benefits business, raises questions about the sustainability of this quarter’s earnings strength.
Management is framing this as a transition year, with Medicaid pressures expected to ease over time and Medicare Advantage and Carelon picking up the slack.
But for now, the market’s reaction suggests investors want to see actual margin improvement before giving Elevance Health stock the benefit of the doubt.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Elevance Health Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
